SyntheX

Takeda Pharmaceutical Co. Ltd. is the latest in a string of pharmaceutical manufacturers investing in molecular glue degraders through dealmaking. The company announced a collaboration with Shanghai-

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr

Genentech is to collaborate with Orionis Biosciences to discover and develop new ‘molecular glue’ medicines, a field which is already attracting much big pharma investment. The biotech will receive

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. BMS Calls On SyntheX, Autolus In Protei